The Medicare Drug Pricing Program will Attract Uncomfortable Attention to the Rest of the Industry

Keckley Report September 4, 2023
Paul Keckley

Last Tuesday, the Center for Medicare and Medicaid Services (CMS) announced the first 10 medicines that will be subject to price negotiations with Medicare starting in 2026 per authorization in the Inflation Reduction Act (2022). It’s a big deal but far from a done deal.

Here are the 10:

• Eliquis, for preventing strokes and blood clots, from Bristol Myers Squibb and Pfizer
• Jardiance, for Type 2 diabetes and heart failure, from Boehringer Ingelheim and Eli Lilly
• Xarelto, for preventing strokes and blood clots, from Johnson & Johnson
• Januvia, for Type 2 diabetes, from Merck
• Farxiga, for chronic kidney disease, from AstraZeneca
• Entresto, for heart failure, from Novartis
• Enbrel, for arthritis and other autoimmune conditions, from Amgen
• Imbruvica, for blood...

Today's Sponsors

Today's Sponsor